AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27305924 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 J dose of near-infrared (NIR) light therapy
Number of subjects: 9
Study 27305924 — intervention group
Group type: COMPARATOR
Intervention: Sham dose
Number of subjects: 9
Study 25914281 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 28
Study 23837606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic treatment (GDHT)
Number of subjects: 460
Study 23837606 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid treatment
Number of subjects: 460
Study 20946674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutoring by physicians with content expertise (n = 5)
Number of subjects: 151
Study 20946674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutoring by physicians with process expertise (n = 3)
Number of subjects: 151
Study 20946674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutoring by a combination of content experts for 11 sessions and process experts for 10 sessions (n = 3)
Number of subjects: 151
Study 20946674 — intervention group
Group type: EXPERIMENTAL
Intervention: Process experts (overall rating from students)
Number of subjects: 151
Study 20946674 — intervention group
Group type: COMPARATOR
Intervention: Content experts
Number of subjects: 151
Study 18257904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin treatment
Number of subjects: 175
Study 18257904 — intervention group
Group type: COMPARATOR
Intervention: Non-ribavirin treatment (Control B)
Number of subjects: 175
Study 18257904 — intervention group
Group type: COMPARATOR
Intervention: Control A (previously healthy subjects)
Number of subjects: 175
Study 16414295 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (25ng/ml and 75ng/ml)
Number of subjects: 0
Study 16414295 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.14mg/kg and 0.28mg/kg)
Number of subjects: 0
Study 16414295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14717279 — intervention group
Group type: EXPERIMENTAL
Intervention: Astigmatic refractive correction
Number of subjects: 0
Study 14717279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 11511130 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to misleading postevent information
Number of subjects: 0
Study 11511130 — intervention group
Group type: COMPARATOR
Intervention: Neutral and leading postevent information
Number of subjects: 0
Study 11511130 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention intervals of 1 day and 6 weeks
Number of subjects: 0
Study 9300118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide during active treatment periods in children with asthma (aged 12-16 years)
Number of subjects: 36
Study 9300118 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method for calculation of growth rates
Number of subjects: 36
Study 9300118 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 36
Study 8337162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (Ativan)
Number of subjects: 24
Study 8337162 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (Compazine)
Number of subjects: 24
Study 3095557 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding via needle catheter jejunostomy (N.C.J.) with an elemental diet (Vivonex HN) starting at 18 hours and advanced to 3,000 ml/day (3,000 kcal, 20 gm N2) within 72 hours.
Number of subjects: 75
Study 3095557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental nutrition during first 5 days).
Number of subjects: 75
Study 30232858 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (30 min, once daily, 6 times a week for 30 days)
Number of subjects: 60
Study 30232858 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride (5 mg/night for 30 days)
Number of subjects: 60
Study 30232858 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 60
Study 30232858 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride
Number of subjects: 60
Study 30232858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27532525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (two doses of 300mg given 1 week apart)
Number of subjects: 71
Study 27532525 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (two doses of 300mg given 1 week apart) + Ketoconazole shampoo (one application)
Number of subjects: 71
Study 24418570 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied bilaterally to the quadriceps muscles, n = 11, 8 weeks, 5 days/week, twice/day, 45 min/session
Number of subjects: 20
Study 24418570 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 9
Number of subjects: 20
Study 22955004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with resin composite (Tetric Ceram)
Number of subjects: 139
Study 22955004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with poly-acid modified resin composite (Dyract AP)
Number of subjects: 139
Study 22955004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with continuous curing technique
Number of subjects: 139
Study 22955004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with soft start curing technique
Number of subjects: 139
Study 22955004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with pulse delay curing technique
Number of subjects: 139
Study 20300024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued session (after Wingate anaerobic protocol)
Number of subjects: 15
Study 20300024 — intervention group
Group type: COMPARATOR
Intervention: Nonfatigued session
Number of subjects: 15
Study 18397984 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (1.0 g daily)
Number of subjects: 116
Study 16231254 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR for respiratory viruses and atypical pathogens
Number of subjects: 107
Study 16231254 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR results reported to treating physician
Number of subjects: 107
Study 16231254 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 107
Study 16231254 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic tests
Number of subjects: 107
Study 12005274 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 635
Study 12005274 — intervention group
Group type: COMPARATOR
Intervention: Frovatriptan (0.5, 1, 2.5, or 5 mg)
Number of subjects: 635
Study 12005274 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan (all doses)
Number of subjects: 635
Study 10701818 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling sessions
Number of subjects: 1367
Study 10701818 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits/discussion groups
Number of subjects: 1367
Study 10701818 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized appointment-tracking system
Number of subjects: 1367
Study 10701818 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1367
Study 9347681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1800 mg of eicosapentanoic acid [EPA] + 1200 mg of docosahexanoic acid) with garlic powder (1200 mg) capsules daily for 1 month
Number of subjects: 40
Study 9347681 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 40
Study 8516490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (calcium antagonist)
Number of subjects: 0
Study 8516490 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 3758388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 49
Study 3758388 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 49
Study 31216247 — intervention group
Group type: EXPERIMENTAL
Intervention: Resealed restorations
Number of subjects: 152
Study 31216247 — intervention group
Group type: COMPARATOR
Intervention: Control restorations
Number of subjects: 152
Study 29064409 — intervention group
Group type: COMPARATOR
Intervention: Control diet (10:1)
Number of subjects: 24
Study 29064409 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐linolenic acid (ALA) diet (2:1)
Number of subjects: 24
Study 29064409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) diet (10:1 plus supplement)
Number of subjects: 24
Study 29064409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (2:1 + S)
Number of subjects: 24
Study 26216528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 48
Study 26216528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous molecules (metabolites such as tryptophan, alanine, arachidonic acid, 2-hydroxybutyric acid, cholesterol, and isoleucine)
Number of subjects: 48
Study 23541216 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental text (lower Flesch-Kincaid reading grade level of 7.4)
Number of subjects: 60
Study 23541216 — intervention group
Group type: COMPARATOR
Intervention: Control text (higher Flesch-Kincaid reading grade level of 9.6)
Number of subjects: 60
Study 23541216 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental text (adjusted for age, education, and health literacy)
Number of subjects: 60
Study 23541216 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental text (limited to persons with college degrees)
Number of subjects: 60
Study 23541216 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental text (limited to persons with no self-reported health literacy problems)
Number of subjects: 60
Study 21502571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar 50 mg daily
Number of subjects: 720
Study 21502571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar 100 mg daily
Number of subjects: 720
Study 21502571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar 200 mg daily
Number of subjects: 720
Study 21502571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 21502571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar (all regimens)
Number of subjects: 720
Study 21502571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar
Number of subjects: 720
Study 21502571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar (higher doses)
Number of subjects: 720
Study 19662793 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose solution (1000 mL) one day before surgery
Number of subjects: 208
Study 19662793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative non‐glucose crystalloid solutions
Number of subjects: 208
Study 19662793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative use of insulin
Number of subjects: 208
Study 19662793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative replacement with cristalloids and insulin
Number of subjects: 208
Study 16445447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM) solution
Number of subjects: 80
Study 16445447 — intervention group
Group type: COMPARATOR
Intervention: Placebo intracamerally
Number of subjects: 80
Study 15538125 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine plus placebo
Number of subjects: 30
Study 15538125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus risperidone
Number of subjects: 30
Study 15538125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine only
Number of subjects: 30
Study 15538125 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation strategy with risperidone
Number of subjects: 30
Study 11273218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 3 months or more
Number of subjects: 551
Study 11273218 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (never breastfed)
Number of subjects: 551
Study 11273218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed breastfeeding
Number of subjects: 551
Study 11273218 — intervention group
Group type: COMPARATOR
Intervention: Other breastfeeding (mixed or formula)
Number of subjects: 551
Study 9634163 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 40
Study 9634163 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 8176922 — intervention group
Group type: EXPERIMENTAL
Intervention: Three courses of cisplatinum containing combination chemotherapy
Number of subjects: 0
Study 8176922 — intervention group
Group type: COMPARATOR
Intervention: Less than three courses of chemotherapy
Number of subjects: 0
Study 3204636 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 0
Study 3204636 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-focus (dispositional self-consciousness)
Number of subjects: 0
Study 31607388 — intervention group
Group type: EXPERIMENTAL
Intervention: TOFR >0.95
Number of subjects: 3150
Study 31607388 — intervention group
Group type: COMPARATOR
Intervention: TOFR >0.9
Number of subjects: 3150
Study 30106253 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram
Number of subjects: 10
Study 30106253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28971615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 2.5 μg
Number of subjects: 28
Study 28971615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 5 μg
Number of subjects: 28
Study 28971615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 10 μg
Number of subjects: 28
Study 28971615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26093872 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg daily
Number of subjects: 1996
Study 26093872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1996
Study 23139058 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (FtF) exercise intervention
Number of subjects: 194
Study 23139058 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone (Tel) exercise intervention
Number of subjects: 194
Study 23139058 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 194
Study 22078184 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of MPA 25 mg + E(2)-Cyp 5 mg
Number of subjects: 30
Study 22078184 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of MPA 25 mg + E(2)-Cyp 5 mg
Number of subjects: 30
Study 22078184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC and IM administration
Number of subjects: 30
Study 18077124 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy throughout pregnancy
Number of subjects: 0
Study 18077124 — intervention group
Group type: COMPARATOR
Intervention: Control group (babies conceived off methadone)
Number of subjects: 0
Study 16365743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 12.5 mg/m(2) plus radiation 36 Gy
Number of subjects: 85
Study 16365743 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol 40 mg/m(2)/carboplatin AUC 1.5 plus radiation 40 Gy
Number of subjects: 85
Study 14626750 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR) program
Number of subjects: 95
Study 14626750 — intervention group
Group type: COMPARATOR
Intervention: Conventional Reduced-Calorie Diet (RCD)
Number of subjects: 95
Study 14626750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MR and RCD programs
Number of subjects: 95
Study 11105938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg per hour)
Number of subjects: 26
Study 11105938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9048349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal
Number of subjects: 84
Study 9048349 — intervention group
Group type: COMPARATOR
Intervention: Prednisone continuation
Number of subjects: 84
Study 8815669 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave sterilization of catheters (800 W for over 6 minutes after washing with water)
Number of subjects: 30
Study 8815669 — intervention group
Group type: COMPARATOR
Intervention: Control group (catheters thoroughly washed before microwave treatment)
Number of subjects: 30
Study 2533878 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% erythromycin and zinc combination (Zineryt)
Number of subjects: 122
Study 2533878 — intervention group
Group type: COMPARATOR
Intervention: 2% erythromycin (Eryderm)
Number of subjects: 122
Study 335571 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopheryl nicotinate (600 mg, 6 capsules a day)
Number of subjects: 60
Study 335571 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60
Study 30040242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanimal chondroitin sulfate (800 mg tablet)
Number of subjects: 0
Study 30040242 — intervention group
Group type: COMPARATOR
Intervention: Animal-derived chondroitin sulfate
Number of subjects: 0
Study 28320635 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipotent adult progenitor cells (400 million cells)
Number of subjects: 129
Study 28320635 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipotent adult progenitor cells (1200 million cells)
Number of subjects: 129
Study 28320635 — intervention group
Group type: COMPARATOR
Intervention: Multipotent adult progenitor cells (combined groups 2 and 3)
Number of subjects: 129
Study 26075918 — intervention group
Group type: EXPERIMENTAL
Intervention: Open/free-spirited dater profile
Number of subjects: 0
Study 26075918 — intervention group
Group type: COMPARATOR
Intervention: Traditional/uptight dater profile
Number of subjects: 0
Study 25141240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact ER OC/APAP 30/1300 mg
Number of subjects: 55
Study 25141240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact IR OC/APAP 30/1300 mg
Number of subjects: 55
Study 25141240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact ER OC/APAP 15/650 mg
Number of subjects: 55
Study 25141240 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ER OC/APAP 30/1300 mg
Number of subjects: 55
Study 22270557 — intervention group
Group type: EXPERIMENTAL
Intervention: Past users of coffee, tea, or alcoholic beverages
Number of subjects: 664
Study 22270557 — intervention group
Group type: COMPARATOR
Intervention: Current users of coffee, tea, or alcoholic beverages
Number of subjects: 664
Study 22270557 — intervention group
Group type: COMPARATOR
Intervention: Never users of coffee, tea, or alcoholic beverages
Number of subjects: 664
Study 20659607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Number of subjects: 32
Study 20659607 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.2 mg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Number of subjects: 32
Study 17987388 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered with telephone support (SA)
Number of subjects: 331
Study 17987388 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-administered (PA)
Number of subjects: 331
Study 15834297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (n = 96)
Number of subjects: 278
Study 15834297 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (n = 78)
Number of subjects: 278
Study 12376504 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeats <22
Number of subjects: 600
Study 12376504 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in CAG length
Number of subjects: 600
Study 12376504 — intervention group
Group type: EXPERIMENTAL
Intervention: GGC repeats
Number of subjects: 600
Study 12376504 — intervention group
Group type: EXPERIMENTAL
Intervention: GGC repeats <=17
Number of subjects: 600
Study 12376504 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG <22 and GGC <=17
Number of subjects: 600
Study 12376504 — intervention group
Group type: COMPARATOR
Intervention: CAG and GGC repeats
Number of subjects: 600
Study 9894041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AE)
Number of subjects: 0
Study 9894041 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical education class (PE)
Number of subjects: 0
Study 8699839 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 20)
Number of subjects: 37
Study 8699839 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 37
Study 1760713 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT solution
Number of subjects: 0
Study 1760713 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT solution
Number of subjects: 0
Study 1760713 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT-containing solution
Number of subjects: 0
Study 1760713 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT-containing solutions
Number of subjects: 0
Study 6291361 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 6.25 mg
Number of subjects: 18
Study 6291361 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 12.5 mg
Number of subjects: 18
Study 6291361 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 12.5 to 50 mg every 8 hours long-term
Number of subjects: 18
Study 6291361 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT)
Number of subjects: 18
Study 6291361 — intervention group
Group type: COMPARATOR
Intervention: Prazosin 5 mg
Number of subjects: 18
Study 6291361 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 25 mg
Number of subjects: 18
Study 6291361 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 18
Study 30299198 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training + Epicatechin (RT+EP)
Number of subjects: 62
Study 30299198 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 62
Study 30299198 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicatechin (EP)
Number of subjects: 62
Study 30299198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 62